DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,187,441,827 | +17.9% | 4,786,145 | +14.0% | 0.33% | +21.1% |
| Q2 2023 | $1,007,358,626 | +73.3% | 4,197,328 | +81.9% | 0.27% | +62.7% |
| Q1 2023 | $581,446,878 | +5.0% | 2,306,963 | +10.6% | 0.17% | -0.6% |
| Q4 2022 | $553,863,901 | +4.9% | 2,086,745 | +2.1% | 0.17% | -3.5% |
| Q3 2022 | $528,058,000 | +21.9% | 2,044,437 | +19.7% | 0.17% | +28.1% |
| Q2 2022 | $433,111,000 | -13.2% | 1,708,390 | +0.4% | 0.14% | +9.8% |
| Q1 2022 | $499,142,000 | -10.6% | 1,701,639 | +0.2% | 0.12% | 0.0% |
| Q4 2021 | $558,531,000 | +8.1% | 1,697,611 | +0.1% | 0.12% | +2.5% |
| Q3 2021 | $516,491,000 | +13.4% | 1,696,527 | -0.0% | 0.12% | +13.2% |
| Q2 2021 | $455,311,000 | +19.2% | 1,696,642 | -0.0% | 0.11% | +14.0% |
| Q1 2021 | $381,899,000 | +38.4% | 1,696,727 | +36.6% | 0.09% | +29.2% |
| Q4 2020 | $275,871,000 | +62.3% | 1,241,878 | +57.3% | 0.07% | +41.2% |
| Q3 2020 | $169,971,000 | +21.7% | 789,351 | -0.1% | 0.05% | +15.9% |
| Q2 2020 | $139,677,000 | +27.7% | 789,896 | -0.0% | 0.04% | +2.3% |
| Q1 2020 | $109,357,000 | -55.2% | 790,092 | -50.3% | 0.04% | -41.1% |
| Q4 2019 | $244,113,000 | +6.3% | 1,590,519 | +0.1% | 0.07% | -2.7% |
| Q3 2019 | $229,550,000 | +1.0% | 1,589,348 | -0.0% | 0.08% | +4.2% |
| Q2 2019 | $227,173,000 | +27.4% | 1,589,509 | +17.7% | 0.07% | +26.3% |
| Q1 2019 | $178,298,000 | -6.6% | 1,350,541 | -27.0% | 0.06% | -13.6% |
| Q4 2018 | $190,827,000 | -5.1% | 1,850,533 | -0.0% | 0.07% | +13.8% |
| Q3 2018 | $201,080,000 | -32.5% | 1,850,542 | -38.7% | 0.06% | -28.4% |
| Q2 2018 | $297,781,000 | +0.9% | 3,017,645 | +0.1% | 0.08% | -3.6% |
| Q1 2018 | $295,253,000 | +5.8% | 3,015,552 | +0.3% | 0.08% | +2.4% |
| Q4 2017 | $279,099,000 | +8.2% | 3,006,887 | -0.0% | 0.08% | +5.1% |
| Q3 2017 | $257,969,000 | -39.6% | 3,007,333 | -40.5% | 0.08% | -41.8% |
| Q2 2017 | $426,855,000 | -1.3% | 5,058,119 | +0.0% | 0.13% | -1.5% |
| Q1 2017 | $432,554,000 | +9.9% | 5,057,333 | +0.0% | 0.14% | +6.2% |
| Q4 2016 | $393,560,000 | -0.7% | 5,056,013 | 0.0% | 0.13% | -2.3% |
| Q3 2016 | $396,341,000 | -61.3% | 5,056,013 | -50.1% | 0.13% | -62.6% |
| Q2 2016 | $1,023,292,000 | +7.7% | 10,131,602 | +1.2% | 0.35% | +6.7% |
| Q1 2016 | $949,961,000 | +2.1% | 10,014,348 | 0.0% | 0.33% | +3.1% |
| Q4 2015 | $930,133,000 | +9.0% | 10,014,348 | 0.0% | 0.32% | +4.3% |
| Q3 2015 | $853,323,000 | -0.4% | 10,014,348 | 0.0% | 0.30% | +8.2% |
| Q2 2015 | $857,128,000 | +3.4% | 10,014,348 | +2.6% | 0.28% | -0.7% |
| Q1 2015 | $828,993,000 | -0.9% | 9,764,348 | 0.0% | 0.28% | 0.0% |
| Q4 2014 | $836,902,000 | +12.8% | 9,764,348 | 0.0% | 0.28% | +10.5% |
| Q3 2014 | $741,895,000 | -17.5% | 9,764,348 | -14.5% | 0.26% | -18.2% |
| Q2 2014 | $898,993,000 | +10.8% | 11,418,687 | +5.6% | 0.31% | +7.2% |
| Q1 2014 | $811,177,000 | -0.5% | 10,815,687 | +2.4% | 0.29% | -3.0% |
| Q4 2013 | $815,619,000 | +11.4% | 10,565,018 | +0.0% | 0.30% | +4.5% |
| Q3 2013 | $732,113,000 | +11.1% | 10,561,348 | +1.4% | 0.29% | +3.2% |
| Q2 2013 | $659,038,000 | – | 10,411,348 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |